Menu

Reports

17696795_l edit

Biosimilars uptake rates in Europe and the UK

Home/Reports | Posted 08/09/2023

The rate of uptake of biosimilars has accelerated as stakeholders have become increasingly comfortable with these products [1]. However, the adoption of biosimilars is lower in regions experiencing low social and governmental trust [2, 3].

Harmonize V13F28

Guidelines for biosimilars around the world

Home/Reports | Posted 13/04/2018

Biosimilar guidelines and regulations are being developed all over the world, as outlined by Huiguo Hu at the Biosimilars Europe Congress [1].

Switching mAb Pfizer V18K30

Non-medical switching of biologicals/biosimilars webinar: Canada, Europe and the US

Home/Reports | Posted 31/08/2023

Biosimilars are now key players in the global drugs market offering potentially more affordable treatment options with similar safety and efficacy. However, there are concerns about non-medical switching practices of originator biologicals/biosimilars in different regions. A webinar was held on 20 July 2022 to discuss non-medical switching practices and to explore the importance of safeguarding the physician–patient relationship [1].

18794124_l

Biosimilar development targets limited range of biologicals

Home/Reports | Posted 31/08/2023

During the Biosimilars Medicines Conference in May 2023, Mr Aurelio Arias from IQVIA delivered a presentation about the biosimilar void in Europe. He highlighted that while the uptake of biosimilars has accelerated, there is a growing disparity in market concentration for smaller biologicals [1].

147 AA010665

Biopharmaceutical industry in Brazil in the 21st century

Home/Reports | Posted 17/08/2023

In Brazil, the approach of the Industrial Economic Complex of Health (Complexo Econômico-Industrial da Saúde, CEIS) has been adopted in the planning of policies related to the health economy. This involves the integration of health, industrial and innovative policies.

138 AA011155

Biopharmaceutical industry in Argentina and Brazil: a 21st century perspective

Home/Reports | Posted 03/08/2023

The biopharmaceutical industries in Latin American countries have gained significant attention in recent years, with an important growth in Argentina and Brazil where the policies implemented have emphasized collaboration between the public and private sector.

Biologicals 3 V13E17

Pharmaceutical companies in China manufacturing copy biologicals

Home/Reports | Posted 20/06/2023

The market for copy biologicals in China has significantly grown over the past decade. The government has been actively promoting the development and use of copy biologicals as a way to improve access to affordable health care. As a result, the number of pharmaceutical companies developing copy biologicals has also increased rapidly and is expected to continue to grow in the coming years.

MD002286

Biosimilars for chronic disease patients

Home/Reports | Posted 19/05/2023

A report which analyses significant developments in the biosimilar space and the impacts on patient access, affordability and quality of care has been released in early 2023. The report is a product of the Patient Access and Affordability Project, a programme of Patients Rising, a non-profit organization.

Latin America V13J25

Study of the use of generic and biosimilar drugs in Latin America

Home/Reports | Posted 12/05/2023

The results of a study on the knowledge, perceptions and use of generic and biosimilar drugs in Latin America and the Caribbean were recently presented at an event organized by the World Bank during the workshop ‘Rethinking Pharmaceutical Policies in Latin America and the Caribbean’ held in Washington DC, USA.

EU-US V19C08

The successful uptake of biosimilars in Europe and the US

Home/Reports | Posted 09/03/2023

US uptake of biosimilars is now beginning to rival that of Europe. This was a take home message from the June 2022 Alliance for Safe Biologic Medicines (ASBM) webinar on the successful uptake of biosimilars in Europe and the US [1].

China-flag

Biosimilar monoclonal antibodies in China

Home/Reports | Posted 10/02/2023

Biosimilar monoclonal antibodies (mAbs) are currently a major focus of research and development in China with policies support. mAbs have become crucial therapeutics for treating diseases such as oncology and autoimmune diseases. As competition from biosimilars increases in China, the price of mAbs is decreasing and access to them is increasing. 

Rheumatology.org V13H09

Biological therapies in patients with rheumatoid arthritis

Home/Reports | Posted 03/02/2023

A study on the estimation of patients with rheumatoid arthritis (RA) as well as those patients who are potentially eligible for the treatment of the disease with biological drugs, was presented by Luca Degli Esposti of CliCon Società Benefit Italy at the 18th Biosimilar Medicines Conference in October 2022.

Checklist V14A17

Highlights of the revised WHO guideline on evaluation of biosimilars

Home/Reports | Posted 13/01/2023

A presentation by Niklas Ekman from the Finnish Medicines Agency during the 18th Biosimilar Medicines Congress in October 2022 in Brussels, Belgium reviewed the key elements of the revised World Health Organization (WHO) Guideline on evaluation of similar biotherapeutic products (SBPs, also called biosimilars) and gave a possible direction for biosimilar regulation in the EU [1].

151 MD002298

Estimation of patients potentially eligible to biological therapies

Home/Reports | Posted 12/12/2022

A study on the estimation of patients with psoriasis, rheumatoid arthritis and inflammatory bowel diseases as candidates for biological therapies was presented by Luca Degli Esposti of CliCon Srl Società Benefit Italy at the 18th Biosimilar Medicines Conference which took place in Brussels, Belgium on 6‒7 October 2022.

05 AA011027

More pro-biosimilar healthcare policies and RWE studies in the US

Home/Reports | Posted 01/12/2022

A 2022 report entitled ‘The U.S. Journey and Path Ahead’ provides perspective on where the US biosimilars industry stands today and what is expected in the future. The publication brought together the latest industry data on biosimilar utilization and payer coverage with survey data from healthcare providers, and thoughts from physicians and experts on biosimilars.

Adalimumab 2 V14A10

Humira (adalimumab) biosimilars pipeline

Home/Reports | Posted 18/11/2022

A large range of biosimilars of the anti-inflammatory drug Humira (adalimumab) are expected to flood the market in 2023. There could be as many as 10+ biosimilar competitors on the market by the end of 2023, based on current US Food and Drug Administration (FDA) approvals and pending applications [1].

ST002293

New and upcoming biosimilars launches in the US

Home/Reports | Posted 04/11/2022

This article provides a summary of newly approved biosimilars and an update on the biosimilar pipeline and those biosimilars in the approval process.

Health Budget 2

CNMC study on the wholesale medicines market in Spain: biosimilar medicines

Home/Reports | Posted 21/10/2022

The National Commission for Markets and Competition (Comisión Nacional de los Mercados y la Competencia, CNMC), the body that promotes and preserves the proper functioning of all markets in the interest of consumers and businesses in Spain, published on 22 June 2022 a study on the regulation of medicine prices in the country, which analyses its main problems and puts forward several recommendations to improve the functioning of the sector, including that of biosimilars, for the benefit of consumers and public health. The research focused on medicines sold through pharmacies. 

19646665_l

Challenges of biosimilar medicines in France

Home/Reports | Posted 14/10/2022

After reviewing the key figures [1] and the incentive measures [2] to promote the use of biosimilars in France, Nadia Amer, speaker at BIOS 22 and Health Economics Analyst at Health Product Department of CNAM, presented the challenges that are faced and that leave still much room for improvement for biosimilar uptake in France [3].

Health Budget 1 V13D12

Incentives promoting use of biosimilar medicines in France

Home/Reports | Posted 06/10/2022

During the presentation at BIOS 22, speaker Nadia Amer described the key figures of biosimilar medicines in France [1], and addressed the incentive measures promoting the use of biosimilar drugs, which have been implemented in France, mostly since 2018 [2].